Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.

Rigosertib achieved a similar OS (8.2 months, 95% CI 6.1–10.1) compared with best supportive care (5.9 months, 95% CI 4.1–9.3) that did not reach statistical significance (HR 0.87, 95% CI 0.67–1.14; p = 0.33). 73 A phase I/II single-agent trial in patients with MDS or MDS progressed to AML showed only one responder of 13 AML patients. 74 Other cell cycle inhibitors Cyclin-dependent kinases (CDK) are a group of proteins that promote transition through the cell cycle.

also in 111,027 other papers